These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
731 related articles for article (PubMed ID: 26920914)
41. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Kaminski RM; Matagne A; Leclercq K; Gillard M; Michel P; Kenda B; Talaga P; Klitgaard H Neuropharmacology; 2008 Mar; 54(4):715-20. PubMed ID: 18207204 [TBL] [Abstract][Full Text] [Related]
42. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Klein P; Schiemann J; Sperling MR; Whitesides J; Liang W; Stalvey T; Brandt C; Kwan P Epilepsia; 2015 Dec; 56(12):1890-8. PubMed ID: 26471380 [TBL] [Abstract][Full Text] [Related]
43. Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus. Willems LM; Bauer S; Rosenow F; Strzelczyk A Expert Opin Pharmacother; 2019 Oct; 20(14):1755-1765. PubMed ID: 31264486 [No Abstract] [Full Text] [Related]
44. Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. Zona C; Pieri M; Carunchio I; Curcio L; Klitgaard H; Margineanu DG Epilepsy Res; 2010 Jan; 88(1):46-54. PubMed ID: 19914041 [TBL] [Abstract][Full Text] [Related]
45. Brivaracetam: First Global Approval. Markham A Drugs; 2016 Mar; 76(4):517-22. PubMed ID: 26899665 [TBL] [Abstract][Full Text] [Related]
46. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events. Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673 [TBL] [Abstract][Full Text] [Related]
47. A review of the pharmacology and clinical efficacy of brivaracetam. Klein P; Diaz A; Gasalla T; Whitesides J Clin Pharmacol; 2018; 10():1-22. PubMed ID: 29403319 [TBL] [Abstract][Full Text] [Related]
48. Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy. Fonseca E; Guzmán L; Quintana M; Abraira L; Santamarina E; Salas-Puig X; Toledo M Epilepsy Behav; 2020 Jan; 102():106657. PubMed ID: 31731108 [TBL] [Abstract][Full Text] [Related]
49. Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities. Theochari E; Cock H; Lozsadi D; Galtrey C; Arevalo J; Mula M Epilepsy Behav; 2019 Jan; 90():129-131. PubMed ID: 30530134 [TBL] [Abstract][Full Text] [Related]
50. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST). Lattanzi S; Canafoglia L; Canevini MP; Casciato S; Chiesa V; Dainese F; De Maria G; Didato G; Falcicchio G; Fanella M; Ferlazzo E; Fisco G; Gangitano M; Giallonardo AT; Giorgi FS; La Neve A; Mecarelli O; Montalenti E; Piazza F; Pulitano P; Quarato PP; Ranzato F; Rosati E; Tassi L; Di Bonaventura C; CNS Drugs; 2021 Dec; 35(12):1289-1301. PubMed ID: 34476770 [TBL] [Abstract][Full Text] [Related]
51. Adjunctive brivaracetam - A prospective audit of outcomes from an epilepsy clinic. Stephen L; Brodie MJ Epilepsy Behav; 2021 Mar; 116():107746. PubMed ID: 33517200 [TBL] [Abstract][Full Text] [Related]
52. Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base. Brandt C; May TW; Bien CG Ther Adv Neurol Disord; 2016 Nov; 9(6):474-482. PubMed ID: 27800023 [TBL] [Abstract][Full Text] [Related]
53. Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy. Gillis RME; Wammes-van der Heijden EA; Schelhaas HJ; Tan IY; Festen DAM; Majoie MHJM Acta Neurol Belg; 2021 Jun; 121(3):677-684. PubMed ID: 32157673 [TBL] [Abstract][Full Text] [Related]
54. Potential role of brivaracetam in pediatric epilepsy. Verrotti A; Grasso EA; Cacciatore M; Matricardi S; Striano P Acta Neurol Scand; 2021 Jan; 143(1):19-26. PubMed ID: 32966640 [TBL] [Abstract][Full Text] [Related]
55. Interaction of Approved Drugs with Synaptic Vesicle Protein 2A. Danish A; Namasivayam V; Schiedel AC; Müller CE Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28220535 [TBL] [Abstract][Full Text] [Related]
56. Adjunctive brivaracetam for patients with refractory partial seizures: A meta-analysis of randomized placebo-controlled trials. Ma J; Huang S; You C Epilepsy Res; 2015 Aug; 114():59-65. PubMed ID: 26088886 [TBL] [Abstract][Full Text] [Related]
57. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. Steinhoff BJ; Staack AM Ther Adv Neurol Disord; 2019; 12():1756286419873518. PubMed ID: 31523280 [TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Ben-Menachem E; Mameniškienė R; Quarato PP; Klein P; Gamage J; Schiemann J; Johnson ME; Whitesides J; McDonough B; Eckhardt K Neurology; 2016 Jul; 87(3):314-23. PubMed ID: 27335114 [TBL] [Abstract][Full Text] [Related]
59. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding. Shi J; Anderson D; Lynch BA; Castaigne JG; Foerch P; Lebon F Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812 [TBL] [Abstract][Full Text] [Related]